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S U M M A R Y
We describe the clinical course of a previously healthy 20-month-old toddler admitted with high fever
and leukocytosis. Blood culture grew Streptococcus pneumoniae serotype 19A, belonging to the ST663
clone, highly resistant to penicillin, ceftriaxone, and erythromycin. The same clone with identical
antibiogram was isolated from the nasopharynx of another three of the other ﬁve healthy children
attending the same daycare center as the patient. This case exempliﬁes the potential problems posed by
highly-resistant S. pneumoniae serotype 19A, an emerging pathogen worldwide.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The 7-valent pneumococcal conjugate vaccine (PCV7), intro-
duced in 2000, was designed to signiﬁcantly lower pneumococcal
diseases rates and to reduce the steadily growing rates of
antibiotic-resistant Streptococcus pneumoniae infections. Following
routine vaccination, a dramatic decline in invasive pneumococcal
disease (IPD) rates was observed as a result of a decrease in
vaccine-type serotypes,1 but it was accompanied by an increase in
the incidence of non-vaccine serotypes in IPD,2 acute otitis media,3
and nasopharyngeal carriage4 (the replacement phenomenon). S.
pneumoniae serotype 19A (SP-19A) is the most important strain
associated with this phenomenon at all sites. In Israel, PCV7 is
licensed and recommended for all children under 2 years of age,
but routine vaccination has not yet started.
The focus on serotype 19A has increased recently, not only
because of its role in the post-vaccination replacement phenome-
non, but also because of increasing multiple antibiotic-resistant
clones of this serotype.5 Nevertheless, reports of community-* Corresponding author. Tel.: +972 3 925 3775; fax: +972 3 925 3801.
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remain limited. We describe a case of SP-19A bacteremia in a
toddler attending a daycare center in Israel. This report is intended
of alert pediatricians of the potential hazards of community-
acquired highly-resistant S. pneumoniae infections, due to a
serotype that cannot be reduced by PCV7 administration.
2. Case report
A 20-month-old toddler presented to the Schneider Children’s
Medical Center of Israel during December 2006 because of fever up
to 41.2 8C, minor cough, and rhinorrhea of 2 days duration. Her
previous medical history was unremarkable, and she was fully
vaccinated according to age (without PCV7) and had not received
antibiotic treatment in the last 6 months before her visit. On
admission, the child appeared well without signs of distress. Her
temperature was 39.6 8C, pulse 142/min, blood pressure 96/45
mmHg, and oxygen saturation 100% at room air. Physical
examination did not reveal a focus of infection. The blood
leukocyte count was 36.07  109/l (77% granulocytes), serum C-
reactive protein (CRP) concentration was 12.3 mg/l (normal
0.5 mg/dl), hemoglobin concentration was 11.4 g/dl, and platelet
count was 346  109/l. Electrolyte levels and renal and liverses. Published by Elsevier Ltd. All rights reserved.
Table 1
Characteristics of the daycare center contacts of the patient
Subject No. Carrier of SP-19Aa Age (months) Chronic illnesses Prior hospitalization Prior antibiotic
treatment
Remarks
1 Yes 12 No No No
2 No 15 No No 1 month before
3 Yes 14 No No 3 months before
4 Yes 13 Thallasemia minor No 3 months before Parents work
in a hospital
5 No 18 No No No
a SP19A - Streptococcus pneumoniae serotype 19A.
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were normal, and a chest X-ray performed on admission revealed
no abnormalities.
Bacteremia was suspected, the child was hospitalized, and
treatment with ceftriaxone (50 mg/kg/day) was initiated. However,
the fever persisted for the next 48 h. A blood culture obtained at
admission grew S. pneumoniae. In vitro studies of antibiotic activity
yielded high resistance to penicillin (minimum inhibitory concen-
tration (MIC) 32mg/ml) and ceftriaxone (MIC 4mg/ml). The
organism was also resistant to erythromycin, showed intermediate
susceptibility to tetracycline, and was susceptible to vancomycin,
rifampin, clindamycin, co-trimoxazole, and levoﬂoxacin. Based on
these results, treatment was switched to vancomycin and rifampin.
Subsequent blood cultures were sterile, and there were no signs of
endocarditis on echocardiography. The fever resolvedwithin 48 h of
administration of the new treatment, and the CRP concentration
gradually decreased to 0.7 mg/l. The child was discharged in good
health following a 7-day course of vancomycin and rifampin.
Nasopharyngeal swabs were obtained from close contacts of
the patient, namely family members and daycare center members.
All were healthy at the present time. Findings for the parents and
grandfather were negative, but three samples taken from the other
ﬁve children in her daycare center grew S. pneumoniae, with
identical antibiograms to the bacteria isolated from the patient
(Table 1). None of the children at the daycare center, their parents
or their siblings suffered from signiﬁcant chronic illnesses, and
none had received PCV7. The parents of a 13-month-old child
worked in a hospital, the father as a gynecologist and themother as
a nurse in the thoracic surgery department. These parentswere not
tested for carriage, but investigation with the microbiology
laboratory of that hospital revealed no reports of isolation of
highly-resistant S. pneumoniae from either department.
The S. pneumoniae isolates from the patient and daycare carriers
were identiﬁed as serotype 19A. Pulsed-ﬁeld gel electrophoresis
demonstrated that all isolates belonged to the same clone.
Multilocus sequence typing identiﬁed the isolate as the ST663
clone.
3. Discussion
Antibiotic resistance among S. pneumoniae isolates emerged as
a signiﬁcant problem during the 1990 s, and is still a major concern
today, evenwith the routine administration of PCV7 in the USA and
Europe. We report the spread in a daycare center of a highly
antibiotic-resistant clone, not covered by PCV7, causing bacter-
emia in one child and carried asymptomatically in the nasophar-
ynx of another three close contacts.
The epidemiology of S. pneumoniae infections differs somewhat
between Israel and the USA and Europe. In Israel, PCV7, which was
licensed only late in 2006 and is scheduled to enter the routine
vaccination program in 2010, is associated with lower coverage of
invasive and mucosal infections owing to the relatively high
infection rates of non-vaccine serotypes.6While in the USA, SP-19A
has emerged in the post-vaccine era as the most common serotypecausing invasive infections (except for empyema inwhich serotype
1 in the most common serotype),2,7,8 in Israel serotype 19A is the
most common pathogen causing IPD in Jewish children under the
age of 3 years.9 Thus, routine vaccination with PCV7 in Israel will
not halt the spread of serotype 19A, and might even enhance it.
Many clones of SP-19A have been described, but only a limited
number of clones were initially associated with high antibiotic
resistance rates. However, several studies in the post-vaccination
erahave found that SP-19Anow includesmore clones thanobserved
before, and an increasing number of them are highly penicillin- and
ceftriaxone-resistant.7,10 This ﬁnding might be explained by
capsular switching, expansion of existing clones, or the introduction
of new clones as part of the replacement phenomenon.
The organism that caused the disease in our patient was
identiﬁed as SP-19A clone ST663. This clone has not been described
frequently; indeed, there is only one report of its association with
invasive disease in the USA, where it was also found to be highly
antibiotic-resistant.11 Its antibiotic resistance proﬁle is unusual,
with an extremely high MIC for penicillin and ceftriaxone. High
MIC values are rarely documented for third-generation cephalos-
porins in IPD: in Israel, only 1/437 strains isolated from children
less than 13 years of age with IPD was considered resistant to
ceftriaxone according to the National Committee for Clinical and
Laboratory Standards (NCCLS) guidelines, with a MIC of 2mg/ml.12
Interpretation of resistance to ceftriaxone among S. pneumoniae
isolates by MIC is site-dependent. According to the NCCLS
guidelines, resistance is established for cerebrospinal ﬂuid (CSF)
isolates if the MIC is 2mg/ml, while for non-CSF isolates the cut-
off is a MIC of 4mg/ml.13 Although ceftriaxone reaches very high
concentrations in the bloodstream, what determines resistance to
it, as to all beta-lactam antibiotics, is the time over theMIC, and not
peak levels. Therefore, an isolate with a highMIC in the blood, such
as in our patient, means a lower time over the MIC and lower
effectiveness of the drug. In our patient subsequent blood cultures
were sterile, but in such caseswe believe the patient is subjected to
persistent bacteremia, sepsis, and spread of isolate to cause focal
infections.
The treatment of children with suspected occult bacteremia
usually consists of amoxicillin or a third-generation cephalosporin.
The spread of such highly penicillin- and ceftriaxone-resistant
strains in the community could lead to an increase in treatment
failure in pneumococcal infections, including invasive diseases,
which are the most disturbing. The 13-valent pneumococcal
conjugate vaccine, which includes serotype 19A and is currently
under development, will hopefully improve the protection against
such highly resistant strains.
In conclusion, highly-resistant S. pneumoniae strains, such as
SP-19A are circulating in the community and might be involved in
invasive infections. Pediatricians, especially in the community,
should be aware of such resistant strains when administering
antibiotics, including third-generation cephalosporins. The 13-
valent pneumococcal conjugate vaccine, under development,
could substantially decrease diseases caused by highly-resistant
pneumococci such as SP-19A.
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